For information info@sentinelbiomedical.com Telephone 919-996-0174

Contact Us

For media requests and inquiries, please contact Stephanie Llorente, PREP Communications 919-271-6491 or sllorente@prepcomm.com.


Company Profile

Sentinel Biomedical is a pioneering comparative health company committed to research and scientific innovation. The company’s primary focus is investigating canine cancers and identifying biological changes and environmental influences that may be shared with human cancers, making canines true watchdogs in the area of human health. By taking a comparative approach to research, the company aspires to accelerate the pace of cancer-related discoveries leading to improved diagnosis, treatment and patient outcomes. Sentinel Biomedical created the world’s first and most rapid and reliable early detection system for canine bladder cancer/TCC/UC, allowing for more timely therapeutic intervention. The company continues to develop innovative cancer detection products with forensic level sensitivity, supported by robust research, proven science and leading genetics and oncology experts.

Headquartered at North Carolina State University’s Centennial Biomedical Campus in Raleigh, N.C., the company was formed in 2015 by Matthew Breen, PhD CBiol FRSB and a team of highly experienced researchers.


Press Releases

 

Vets, Breeders and Dog Owners Rejoice: New Raleigh Comparative Health Company Offers Pioneering Canine Cancer Detection with Human Health Implications

Sentinel Biomedical Unveils Nation’s First Reliable and Most Sensitive Early Detection System for Canine Bladder Cancer

Groundbreaking Comparative Oncology Realizes Value of Pets as Human Health Watchdogs

Raleigh, N.C. (Nov. 3, 2016) – After applying robust and innovative comparative oncology research, Sentinel Biomedical, a new Raleigh, N.C.-based comparative health company, is rolling out the nation’s first reliable early cancer detection system for dogs and encouraging dog owners to opt into a nationwide study to better understand links between canine and human cancers. The company’s groundbreaking work positions dog owners across the globe to make well-informed health care decisions, inclusive of early intervention and treatment options, while taking an active role in advancing human health care.

At the forefront of these new capabilities is Sentinel Biomedical’s new diagnostic and monitoring tool, the CADETSM BRAF Mutation Detection Assay. The free-catch urine analysis product has proven to be the most sensitive and reliable early transitional cell carcinoma/urothelial carcinoma (TCC/UC) detection system to produce rapid results and allow for early intervention in the treatment of canine bladder cancer. Since TCC/UC may affect up to 80,000 dogs in the U.S. each year, access to this forensic level screening allows veterinarians to provide non-invasive, high quality care to canine patients. Early detection of bladder cancer, several months before symptoms ever display, creates additional time for dog owners to work with veterinarians on treatment plans, potentially extending the life of their pet and saving money on expensive treatment down the road. By actively monitoring treatment progress, veterinarians can adjust their therapeutic strategy as needed for the best possible outcome.

“The CadetSM BRAF Mutation Detection Assay has the potential to be a game changer in how we diagnose transitional cell carcinoma in dogs and possibly how we manage these dogs during treatment,” said Shelly Vaden, DVM, PhD, DACVIM, professor of internal medicine at North Carolina State University’s College of Veterinary Medicine and past president of the American Society of Veterinary Nephrology and Urology. “Today, we typically work through a series of tests to diagnose dogs after they develop clinical signs, at which point the disease has already progressed. Detection of TCC before signs display lets veterinarians transition from diagnostic testing to therapeutic testing – a welcome shift for vets and dog owners alike.”

While this is a much needed tool for veterinarians, the CADETSM BRAF Mutation Detection Assay also offers additional benefits to breeders and dog owners who want peace of mind when it comes to canine health. Early detection of TTC/UC allows dog owners to take control of their pet’s health while making a positive impact on human health. As part of the testing process, dog owners have an opportunity to join a nationwide study to better understand environmental impacts tied to cancer in dogs and in humans, making canines true watchdogs in the area of human health.

Sentinel Biomedical formed as a result of the innovative comparative oncology research taking place at North Carolina State University’s College of Veterinary Medicine by Dr. Matthew Breen and a team of highly experienced researchers.

“After more than 20 years in comparative oncology research, I have learned that on the road to new discoveries in cancer research, the answers to unlocking some of nature’s most intriguing puzzles are walking right beside us,” said Matthew Breen, PhD CBiol FRSB, founder of Sentinel Biomedical and the Oscar J. Fletcher distinguished professor of comparative oncology genetics at North Carolina State University’s College of Veterinary Medicine. “Sentinel Biomedical is helping dog owners around the globe realize that man’s best friend is also man’s best biomedical friend.”

The American Kennel Club (AKC), the nation’s most respected advocate for dogs, is helping to bring Sentinel Biomedical’s early cancer detection products to breeders and dog owners.

“In keeping with our long-standing commitment to canine health and well-being, the American Kennel Club is pleased to offer Sentinel Biomedical’s early cancer detection products to visitors of AKC.org, and we hope that more dog owners will participate in Dr. Breen’s ongoing research,” said Mark Dunn, AKC senior vice president of registration and customer development.

The Sentinel Biomedical CADETSM BRAF Mutation Detection Assay can be purchased by owners as an annual screening subscription to screen one dog three times a year, as an initial screening pack for breeders to test multiple dogs at once, or as a diagnosis/monitoring tool for veterinarians. The assay is exclusively available through Sentinel Biomedical’s website and the AKC’s online store.

Attendees of the North Carolina Veterinary Conference can visit the Sentinel Biomedical booth at the Raleigh Convention Center Nov. 4-6 to learn more about the research, the company and the product.

Additional educational videos on Sentinel Biomedical’s unique perspective on cancer research can be found here.

Editor’s Note: Dr. Matthew Breen is available for interviews and would be happy to explain this state-of-the-art biomedical news in more detail. Please contact Stephanie Llorente at sllorente@prepcomm.com or 919-271-6491 to set up an interview.

About Sentinel Biomedical

Sentinel Biomedical is a pioneering comparative health company committed to research and scientific innovation. The company’s primary focus is investigating canine cancers and identifying biological changes and environmental influences that may be shared with human cancers, making canines true watchdogs in the area of human health. By taking a comparative approach to research, the company aspires to accelerate the pace of cancer-related discoveries leading to improved diagnosis, treatment and patient outcomes. Sentinel Biomedical created the world’s first and most rapid and reliable early detection system for canine bladder cancer/TCC/UC, allowing for more timely therapeutic intervention. The company continues to develop innovative cancer detection products with forensic level sensitivity, supported by robust research, proven science and leading genetics and oncology experts.

Headquartered at North Carolina State University’s Centennial Biomedical Campus in Raleigh, N.C., the company was formed in 2015 by Matthew Breen, PhD CBiol FRSB and a team of highly experienced researchers. Learn more at www.SentinelBiomedical.com.


In The News


Scientific Publications

Coming soon!